Happy Friday eve!
🇺🇸 Programming note: Axios will be taking Veterans Day off to show our appreciation for those who served.
Some personal news: 👋 Hey, Sarah here. Today’s my last on the Axios Health Tech Deals beat. It’s been an awesome ride, but I’m off to try something new. Thanks for reading, and a special thanks to all my talented colleagues. Stay in touch!
🚨 Claire Rychlewski, our savvy editor, will be stepping in. Send her your tips and say hello!
1 big thing: Warburg’s ModMed mulls stake sale
Modernizing Medicine and its largest investor, Warburg Pincus, are evaluating a partial-stake sale of the specialty electronic health records giant, sources familiar with the matter tell Sarah.
Why it matters: ModMed, along with Blackstone’s HealthEdge Software, will represent a good test case for the new valuation reality in health tech investing if a deal gets done. It’s been several months since we’ve seen scaled, growth-oriented SaaS companies test the market.
What’s happening: The Boca Raton, Florida-based company formally hit the market in October, with first-round bids from sponsors due around mid-November, sources say.
- Evercore is providing financial advice to Warburg and ModMed.
- Sources caution that Warburg and the company may choose not to transact, depending on where interest levels and valuation appetite land.
By the numbers: ModMed, which has been investing heavily in R&D to fuel future growth, generates around $400 million of ARR, sources say.
- Warburg’s current stake lies at roughly 40%, sources say.
- Other small minority investors that invested early in ModMed’s evolution include Pentland Group, Summit Partners and Sands Capital.
Flashback: A year ago, sources pegged ModMed as a likely IPO candidate, but that was a much different market.
How it works: ModMed designs cloud-based and data-driven EHR software products tailored to a vast range of medical specialties, including dermatology, gastroenterology, plastic surgery and orthopedics.
- Warburg invested an initial $231 million into the company in 2017.
The bottom line: ModMed is a bellwether for other growth-focused SaaS investors, who will be watching closely to see if the company overcomes market woes to attract a 2021-like valuation — or lands something much more conservative.
Warburg declined to comment. ModMed did not immediately respond to a request for comment.
More Stories
CES 2023: AI, smart health and the metaverse set to dominate this year’s tech show in Vegas
The 2023 Men’s Health Tech Awards
Smart Household, Overall health Tech, and Anything Else We Saw at CES